Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Peter Wolf, MD"'
Autor:
VijayKumar Patra, PhD, Nora Woltsche, MD, Urban Cerpes, MD, Danijela Bokanovic, MD, Maria Repelnig, MD, Aaroh Joshi, MSc, Isabella Perchthaler, MSc, Manuela Fischl, PhD, Marc Vocanson, PhD, Natalie Bordag, PhD, Marija Durdevic, MSc, Johannes Woltsche, MD, Franz Quehenberger, PhD, Franz Legat, MD, Andreas Wedrich, MD, Jutta Horwath-Winter, MD, Peter Wolf, MD
Publikováno v:
Ophthalmology Science, Vol 4, Iss 1, Pp 100340- (2024)
Objective: To elucidate the pathogenesis of dupilumab (Dupixent®)–associated ocular surface disease (DAOSD). Design: Prospective single-center cohort study. Subjects: Twenty patients with moderate-to-severe atopic dermatitis (AD) who received dupi
Externí odkaz:
https://doaj.org/article/d378970f1c4d414f99184f99e0433ec2
Autor:
Thomas Graier, MD, Wolfgang Weger, MD, Paul-Gunther Sator, MD, Wolfgang Salmhofer, MD, Barbara Gruber, MD, Constanze Jonak, MD, Claudia Kölli, MD, Martina Schütz-Bergmayr, MD, Igor Vujic, MD, Gudrun Ratzinger, MD, Nina Häring, MD, Clemens Painsi, MD, PhD, Knut Prillinger, MD, Alexander Mlynek, MD, Hans Skvara, MD, Hannes Trattner, MD, Adrian Tanew, MD, Roland Lichem, MD, Christina Ellersdorfer, MD, Franz Legat, MD, Alexandra Gruber-Wackernagel, MD, Angelika Hofer, MD, Erich Schmiedberger, MSc, Wolfram Hoetzenecker, MD, PhD, Robert Müllegger, MD, Werner Saxinger, MD, Franz Quehenberger, PhD, Peter Wolf, MD
Publikováno v:
JAAD International, Vol 2, Iss , Pp 62-75 (2021)
Background: Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions. Objective: To investigate the influence of patient and disease characteristics on drug survival associated with apremilast a
Externí odkaz:
https://doaj.org/article/648c20cfa91b403eb35f5ba5638ed651